Craig van Kampen

Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA.

Medtronic, Inc. operates as a medical technology company. It offers implantable cardiac pacemakers, eternal defibrillators, inferior turbinate surgery products, and continuous glucose monitoring device. The company was founded by Earl E. Bakken and Palmer J. Hermundslie on April 29, 1949 and is headquartered in Minneapolis, MN.

Silverback Asset Management LLC (Silverback) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Chapel Hill, North Carolina. The firm was founded by Elliot Bossen in 2002. Silverback offers investment solutions for qualified institutional investors which includes pension funds, endowments, insurance companies, fund of funds, family offices and others.

Solace Therapeutics, Inc. develops non-surgical treatments for common bladder disorders. It offers medical devices for stress urinary incontinence, overactive bladder, male voiding dysfunction, and lower urinary tract symptoms. The company was founded by Kevin G. Connors in 2002 and is headquartered in Framingham, MA.

IlluminOss Medical, Inc. engages in the designing, developing, and marketing of orthopedic fracture repair products. The company was founded by Robert A. Rabiner and Arnold-Peter C. Weiss in 2007 and is headquartered in East Providence, RI.

VytronUS, Inc. develops imaging and therapeutic capabilities of ultrasound energy to treat cardiac arrhythmias. The firm develops a catheter-based ablation platform based on low-intensity collimated ultrasound (LICU) which allows for precise non-contact energy delivery and producing high-resolution maps of cardiac anatomy. The company was founded by Hira V. Thapliyal in 2006 and is headquartered in Sunnyvale, CA.

Ivantis, Inc. develops technology to treat ophthalmic diseases. The firm develops solutions for glaucoma and offers an intracanalicular scaffold or implantable device that relieves high intraocular pressures in patients. It provides its solutions for use in clinical trials to ophthalmology specialists. Ivantis was founded in 2007 and is headquartered in Irvine, CA.

Ocutherix, Inc. operates as a medical device incubator which focuses on novel medical technologies. The firm serves the ophthalmology, cardiology, mobile health, orthopedics, neurology, pulmonology and metabolic clinical solutions. The company was founded by Robert E. Atkinson in 2005 and is headquartered in Stillwater, MN.

Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

Morgan Stanley Venture Partners (MSVP) is a venture capital firm subsidiary of Morgan Stanley Investment Management Merchant Banking, which is ultimately owned by Morgan Stanley (NYSE: MWD) founded in 1986.The firm is headquartered in New York.

New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California.

Digi-Key Corp. distributes electronic components. It also distributes semiconductors, discrete, electromechanical parts. Its products include audio products, batteries, cable assemblies, capacitors, computer & video accessories, connectors, crystals & oscillators, discrete semiconductor products and many more. The company was founded by Ronald A. Stordahl in 1972 and is headquartered in Thief River Falls, MN.

Part of Japan Lifeline Co., Ltd., Cardiac Rhythm Management is a company that manufactures implantable devices to treat arrhythmias. The company is based in Sylmar, CA.

Part of Boston Scientific Corp., Cardiac Pacemakers, Inc. is a company that specializes in implanting pacemakers in patients with an abnormally low heart rate. The company is based in St. Paul, MN. The pacemakers are implanted under the skin, in the chest area, and are connected to the heart by transvenous leads that conduct electrical impulses to pace the heart and restore a normal heart rhythm. Patients implanted with a pacemaker must be regularly monitored by their cardiologist to ensure that the pacing system is working correctly. The company was founded by Manny A. Villafana.

Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom.

ClarVista Medical, Inc. operates as a medical device company which focuses on the novel solutions in ophthalmology. It develops the harmoni modular intra-ocular lens systems to optimize vision in the setting of cataract surgery. The company was founded by Paul McLean and Robert E. Atkinson in 2012 and is headquartered in Aliso Viejo, CA.

Cardionomic, Inc. engages in the development of medical devices. The company was founded in 2011 and is headquartered in New Brighton, MN.

MIACH Orthopaedics, Inc. engages in developing of bio-engineered surgical implants for connective tissue repair. The company was founded by Martha Murray and is headquartered in Westborough, MA.

New Enterprise Associates LLC is an alternative investment manager. The private company is based in Timonium, MD. The company was founded in 1978 by Chuck Newhall, C. Richard Kramlich.

Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

858 Therapeutics, Inc. operates as a pharmaceutical company. The company was founded in 2019 and is headquartered in San Diego, CA.

Spyglass Ophthalmics, Inc. develops products for vision and eye care. The company was founded by Malik Y. Kahook and Glenn Sussman and is headquartered in Mission Viejo, CA.

Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022.

Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane.